Last updated: February 14, 2026
What is NDC: 00781-7313?
Its product is a biosimilar version of trastuzumab (Herceptin), a monoclonal antibody indicated for HER2-positive breast, gastric, and other cancers. The drug's label specifies intravenous administration. The biosimilar has received FDA approval, indicating it meets regulatory standards for safety, efficacy, and quality comparable to the reference product.
Market landscape
Therapeutic context
- Trastuzumab (Herceptin) generates approximately $6.7 billion annually globally, with U.S. sales accounting for roughly $3.3 billion in 2022.
- The biosimilar market for trastuzumab has grown rapidly since first biosimilars entered the U.S. market in 2017, capturing over 70% of the market share by 2022.
Competitive positioning
- Key biosimilars approved include Pfizer's Trazimera (trastuzumab-qyyp), Amgen's Kanjinti (trastuzumab-anns), and Samsung Bioepis/Merck's K-Thermer (trastuzumab-deruxtecan).
- Price competition has driven discounts of 20-40% compared to the reference product list prices.
Market penetration factors
- Adoption depends on provider familiarity, insurance coverage, and hospital contracting.
- Cost savings drive payer adoption, especially for value-based treatment settings.
- Biosimilar prescribing has risen from 10% in 2019 to 65% in 2022 in the United States.
Distribution channels
- Institutional procurement dominates, including hospital and oncology clinics.
- Retail pharmacy penetration is limited, but increasing through specialty pharmacy networks.
Price projections
Current pricing (as of Q1 2023)
| Source |
Approximate Wholesale Price |
Estimated Outpatient Cost (per dose) |
| Reference product (Herceptin) |
$6,000–$6,500 |
$120,000–$130,000 (per full course) |
| Biosimilar (NDC: 00781-7313) |
$4,200–$5,000 |
$84,000–$100,000 (per full course) |
Note: Prices vary by payer contracts, geographic location, and delivery setting.
Price decline trajectory
- Biosimilar prices initially trail reference by 20-30%.
- Over the next 2-3 years, prices are expected to decline further by 10% annually due to increased market penetration and manufacturing efficiencies.
- A mid-term projection places biosimilar prices at approximately 25-30% discount over the reference product in 2025.
Key influencing factors
- Patent litigation and market exclusivity expiry timelines.
- Payer incentives for cost savings.
- Manufacturer capacity to scale production and reduce costs.
- Regulatory dynamics regarding interchangeability status.
Revenue estimates
- Assuming the biosimilar captures 50% of the U.S. trastuzumab market by 2024, sales could reach:
| Variable |
Calculation |
Result |
| Market size (annual U.S. sales) |
$3.3 billion |
- |
| Percentage market share |
50% |
- |
| Average price discount |
25% |
- |
| Annual biosimilar sales |
$1.65 billion (50% of reference sales, at 25% discount) |
- |
Strategic outlook
- The biosimilar is positioned to significantly pressure the reference product's market share.
- Future price reductions will likely align biosimilar prices with international markets, where discounts of 30-40% are typical.
Regulatory and policy impacts
- The FDA's approval of interchangeable biosimilars could facilitate substitution at pharmacy level, further decreasing prices.
- State laws on pharmacy substitution and interchangeability influence market dynamics.
- Payer formulary strategies favor biosimilars to manage costs.
Key drivers and risks
- Drivers: Price competition, patent expiry, escalating healthcare costs.
- Risks: Patent litigations, market rejection, slow adoption, manufacturing issues.
Key Takeaways
- NDC: 00781-7313 is a biosimilar to trastuzumab with market entry cemented by FDA approval.
- Biosimilar prices are approximately 20-40% lower than reference Herceptin, with a trend toward further discounts.
- The biosimilar could reach half of the U.S. trastuzumab market by 2024, generating significant revenue.
- Market growth depends on payer policies, provider adoption, and regulatory determinations of interchangeability.
- Continued price erosion is anticipated as manufacturing scale increases and market competition intensifies.
FAQs
1. How does the biosimilar pricing compare to the original trastuzumab?
Prices are generally 20-40% lower, with the biosimilar retailing around $4,200–$5,000 per dose compared to $6,000–$6,500 for the reference.
2. What factors influence biosimilar market share?
Provider acceptance, payer formulary inclusion, regulatory considerations, and price competitiveness.
3. Will the biosimilar be interchangeable with Herceptin?
FDA approval of interchangeability will enable automatic substitution, likely accelerating market share.
4. When is the biosimilar expected to significantly impact the trastuzumab market?
Market momentum suggests notable impact by 2024-2025, as adoption and prices stabilize.
5. How do international prices of biosimilars compare?
In Europe and Asia, biosimilar discounts often reach 30-40%, similar to projections for the U.S. in the medium term.
Citations
[1] IQVIA, "U.S. Oncology Market Report," 2022.
[2] FDA, "Approved Biosimilars," 2023.
[3] ASCO, "Biosimilar Adoption Trends," 2022.
